Among the 169 DEGsSD, 19 were proto-oncogenes (AURKA, CSF1R, EGFR, ETS1, ETV1, FGR, FOS, HCK, KIT, LYN, MECOM, MET, NRAS, PDGFRA, PDGFRB, PTTG1, REL, SPI1, and ZBTB16), nine were relatively specific to the (human) prostate (ARG2, CHRM1, CREB3L4, CXCL10, KLK2, NKX3-1, SLC45A3, SRD5A2 and TMPRSS2), thirteen were orthologs to genes on commercial human PCa multi-gene assays (BUB1B, CDK1, COL1A1, FOS, IQGAP3, KLK2, ORC6, PLK1, PTTG1, RAD51, RRM2, SRD5A2 and THBS2), and 80 were druggable, including 75 (94%) upregulated genes (Figure 4B, Table S1). The gene discussed is KIT; the disease is posterior cortical atrophy.